Those at risk of osteoporosis should maintain an adequate dietary intake of calcium and vitamin D: calcium and vitamin D must be prescribed with all oral and intravenous bone active therapies unless a patient is hypercalcaemic or has a risk of hypercalcaemia, eg sarcoidosis, has had renal stones in the past year or where renal impairment dictates that alfacalcidol should be an alternative.

  • Where patients on bone-active therapy for osteoporosis are intolerant of Adcal D3®/Calci-D®, consider colecalciferol capsules/tablets 800 units daily. For further information on the use of vitamin D outwith this patient group refer to section 9.6.
  • The dose should be to the equivalent of 1000mg of calcium per day and 20 micrograms (800 units) of vitamin D
  • To avoid any potential interaction when taken within 4 hours of a bisphosphonate, consider prescribing calcium and vitamin D supplements to be taken at bedtime, when the stomach is more likely to be empty, to minimise calcium loss.
  • For patients with peanut/soya allergy prescribe Adcal D3® caplets, Calci-D® tablets or colecalciferol tablets.
  • Calcium and vitamin D as monotherapy has only been shown to be effective in osteoporosis in ambulant nursing home residents however this should not be used in place of a proper fracture assessment in these individuals.
  • For further information refer to The Royal Osteoporosis Guidelines: Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management.

ADCAL-D3® - (First line)

Important: Formulation and dosage details

Formulation:

Chewable tablets (calcium 600mg or 15mmol, vitamin D 10 micrograms or 400 units/tablet) (lemon or tutti-frutti flavour)

Dosage:

Tablets, 2 tablets at bedtime or one tablet twice daily.  Advise patients to avoid taking within 4 hours of a bisphosphonate.

Important: Formulation and dosage details

Formulation:

Caplets (calcium 300mg or 7·5mmol, vitamin D 5 micrograms or 200 units/caplet)

Dosage:

2 caplets twice daily.  Advise patients to avoid taking within 4 hours of a bisphosphonate.

Important: Formulation and dosage details

Formulation:

Effervescent tablets (calcium 600mg or 15mmol, vitamin D 10 micrograms or 400 units/tablet) (contain 52mg sodium per tablet)

Dosage:

2 tablets at bedtime or one tablet twice daily.  Advise patients to avoid taking within 4 hours of a bisphosphonate.

CALCI-D® - (First line)

Important: Formulation and dosage details

Formulation:

Chewable tablets (calcium 1000mg or 25mmol, vitamin D 25 micrograms or 1000 units/tablet)

Dosage:

1 tablet in the evening.  Advise patients to avoid taking within 4 hours of a bisphosphonate.

COLECALCIFEROL

Important: Therapy notes

Patients with peanut allergy should avoid the capsules which may contain arachis (peanut) oil. The tablets do not contain arachis (peanut) oil and are suitable for those with peanut allergy.

Important: Formulation and dosage details

Formulation:

Capsules (vitamin D) 20 micrograms (800 units)

Dosage:

By mouth, patients on bone-active therapy for osteoporosis who are intolerant of Adcal-D3®/Calci-D®, 800 units daily.

Important: Formulation and dosage details

Formulation:

Tablets 20 micrograms (800 units)

Dosage:

By mouth, patients on bone-active therapy for osteoporosis who are intolerant of Adcal-D3®, 800 units daily.

Important: Formulation and dosage details

Formulation:

Capsules 500 micrograms (20 000 units)

Dosage:

By mouth, prior to zoledronic acid or denosumab where there is a concern about vitamin D deficiency prior to treatment, 40 000 units weekly for 7 weeks.

Editorial Information

Document Id: F185